LND topic: recursion-pharmaceuticals page 1

recursion pharmaceuticals

China Tightens Rules, US Reacts Quietly

April 30, 2026

Beijing introduced new trade rules that could make it harder for foreign companies to move their production away from China. The changes were announced just before President Trump’s visit to Shanghai for talks with Xi Jinping. The rules aim to punish firms that reduce their reliance on Chinese supp

business

A Small Win in Cutting Drug Costs

April 24, 2026

The White House plans to reveal a new deal with Regeneron Pharmaceuticals on pricing for their drugs. This move comes after the company was one of the few chosen to negotiate. Regeneron, which makes treatments like the Covid-19 antibody combo, didn’t comment right away. Their stock price jumped ove

science

Science superstars from Boston shine at major awards night

April 19, 2026

Four Boston-based scientists walked away with top honors from an awards event that values breakthroughs more than Hollywood does. Held on a Saturday in Los Angeles, the ceremony recognizes discoveries that can take a decade or more to prove, unlike Oscars that focus only on the previous year’s films

politics

Behind the Curtain: How Power Really Works

April 14, 2026

Many people wonder who truly holds the reins of society. Instead of a single shadowy figure pulling strings, a tangled web of institutions, corporations, and elites shape the world from behind the scenes. A deep-dive documentary series explores this web by breaking down how different sectors—educati

finance

Jazz Pharma: A Hot Pick for Smart Buyers

March 28, 2026

The biopharma firm Jazz Pharmaceuticals is making headlines because its shares have surged nearly 50 percent in the last year. The company focuses on drugs for sleep disorders and cancer, with two main products—Xywav and Xyrem—helping people who suffer from narcolepsy. Those medicines have become th

finance

Ligand’s Stock Rises After Bank of America Adds a Buy Rating

March 11, 2026

Bank of America has added Ligand Pharmaceuticals to its list of stocks it recommends buying, setting a new price target at $244. The move comes as the bank highlights Ligand’s business model, which focuses on high‑margin products and a lower level of risk compared to many other biopharma companies.

business

Drug Companies Scramble to Join Trump's Pricing Plan

February 12, 2026

Pharmaceutical firms not included in President Trump's drug pricing agreements are now trying to negotiate their own deals. This move is aimed at avoiding potential tariffs and new pricing regulations. Industry insiders reveal that these companies are reaching out to the White House and Medicare off

environment

America's Hidden Poison: The Truth About Farmland and Sewage Sludge

January 23, 2026

America's farmlands are facing a serious issue. Sewage sludge, often called "biosolids, " is being spread on fields as fertilizer. This sludge contains harmful chemicals and waste from homes and industries. The EPA allows this practice through a rule called the 503 rule. This rule does not make the

politics

Trade Tensions Rise: US Official Suggests EU Should Handle Greenland Tariff Issue Independently

January 18, 2026

The U. S. has a message for Europe: deal with Greenland tariffs on your own. Jamieson Greer, the U. S. Trade Representative, said it's Europe's call whether to tie the Greenland issue to their trade deal with the U. S. He made these remarks at the Detroit Auto Show, suggesting Europe should separate

business

Pharma's Future: How Contract Manufacturing is Changing the Game

January 16, 2026

The world of pharmaceuticals is changing fast. Companies are teaming up to innovate, strengthen their supply chains, and get their products to market. This shift is big news, and it's important for anyone making decisions in this field to stay informed. The market for contract manufacturing in phar